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DEAN'S MESSAGE 

Dr. G.M.H. Shires, Dean, College of Veterinary Medicine 
August 1998 
I hope that you enjoy the new format for this annual report. It certainly makes it more 
attractive and, I am sure, much more readable. Dr. Potgieter and his staff, along with the 
College's Office of Veterinary Medical Communications, put many long hours into this 
production . We offer our thanks to them for a job well done . 
Once again, the faculty of the Center of Excellence have been most productive and, as 
usual, have performed far above the required benchmarks. Many of them have been 
invited to present at international meetings as well as national scientific forums. 
Careful management of the funds and strict adherence to gUidelines have allowed the 
COE to provide quite generous start-up packages for new researchers as well as a 
modest amount of money for equipment purchases for several researchers . The return on 
the state of Tennessee is investment is still a very good one and it would certainly enhance 
our research program if this investment could be increased as the cost of equipment and, 
therefore, the cost of doing research, rises every year. 
The careful dispensation of the funds from this Center has been instrumental in assisting 
new researchers in successfully obtaining extramural funding as well as supporting some 
of our established researchers who may have a gap in their external funding. The COE 
continues to be the backbone which gives support to our entire research effort and is a 
sound investment in relation to funds from external sources . 
My thanks to the state of Tennessee for its continuing support of the Center. Thanks also to 
the researchers who continue to be so productive and to our research leadership who are 
such excellent stewards of the COE. I hope you enjoy this publication. 
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PROGRAM REPORT 

Dr. Leon N.D. Potgieter, Director of Research and Graduate Programs 
I am pleased to report on an active year for the Center of 
Excellence in livestock Diseases and Animal Health in 1997. Once 
again the Center has met its objectives admirably. The number of 
peer-reviewed scientific publications published by faculty supported 
by the Center continues to be truly astounding. These faculty have 
presented their work as seminars or as posters at local, regional, na­
tional and international scientific meetings and other venues. Research 
results are disseminated, not only in prestigious, peer-reviewed interna­
tional journals, but also in popular journals and magazines distributed 
regionally and nationally. Several of our investigators, such as Drs. 
Rouse, Schuller, Brian, Stephen Oliver and Jack Oliver, have been 
invited to give keynote presentations at international scientific meet­
ings. 
The annual report this year has been prepared in a format 
different from previous years. We have chosen to focus on the activi­
ties and achievements of those individuals and research teams whose 
laboratories constitute the core of the Center. These investigators de­
serve tremendous credit for bringing recognition to the College of Vet­
erinary Medicine, the Institute of Agriculture and the University of Ten­
nessee. Furthermore, they continue to ensure that the Center maintains 
its strong competitive position and contribute to the fiscal health of our 
research environment. This report format emphasizes the strength of 
the Center and gives a clearer indication of how it meets its objectives. 
Accomplishments 
It should be evident from reading the summaries of the labora­
tories featured in this report that the Center: 
1 . 	 Improves the quality of human life by improving animal 
health. 
2. 	 Augments livestock disease research capabilities in the 
Institute of Agriculture. 
3. 	 Identifies and characterizes laboratory and animal 
models of important human diseases. 
4. 	 Studies animal/laboratory models for better understand­
ing of human health. 
5. 	 Studies the mechanisms of disease development and 
characterizes causative agents of common diseases im­
4 
., 

.. 
.. 
.. 

portant to the state of Tennessee. 

Improves the capabilities of the College of Veterinary Medi­

cine, the College of Agricultural Sciences and Natural Re­
., 
sources and the Agricultural Experiment Station to deal with 
.. 

diseases. 

Improves the facilities to enable the College of Veterinary 

Medicine to study more effectively infeclious and toxic dis­

eases of animals . 

.. 

8. Disseminates through the Extension praclical infor­
.. 

mation requi to reduce the incidence of livestock dis­
eases . 
., 
.. 

9. Develops new strateg ies for the prevention disease . 

10. Improves facilities and expertise in order to prOVide im­
., 
., proved training . 
., 1 1 . Develops innovative approaches to the treatment of hu­
., man diseases . 
., 
.. 
., 	 Research Funding 
., 	 An important goal of the Center of Excellence is to support re­
., 	 searchers and to promote research by a variety of mechanisms. The 
ter of Excellence in livestock Diseases and Human Health emphasizes the 
following six specific areas: Infeclious Diseases/Population Medicine, Toxi­
.. 	 cology, Reproduction, Defense, Molecular Genej'ics, and Carcino­
., The Center's underlying philosophy is to enhance young (or new) 
investigators' capacity to compete for extramural funding and to assist 
., established researchers to maintain their extra-mural support. The 
does not serve as a primary source of research funding for faculty. The 
., main criteria used for funding proposals include scientifiC merit, likelihood 
of leading to extramural funding and relevance to Center's obiectives. 
.. Proposals are reviewed by the Research and Graduate Programs Advisory 
Committee, and has a representative from every department of the Col­
.. lege of ry Medicine, chai by Dr. David Slauson .. 
The supported the following proiects over the past year: 
.. 
.. 
., 1 . Dr. David Bemis: Recombinant Bordetella bronchiseptica 
fimbriae as carriers of unrelated antigens . 
., 2 . Dr. Philip Bochsler: Cloning bovine CD 14, a patho­
., genrecognition receptor. 
3. Dr. David Brian: How two terminal genej'ic structural 
.. elements regulate replication the coronavirus RNA ge­
.. nome. 
.. 4 . Dr. Kevin Hahn: Reversal of cisplatin resistance using 
.. ethacrynic acid: Evaluation in an osteosarcoma animal
.. model . 
.. 
.. 
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5. 	 Dr. Alan Mathew: Characterization of mastitis-causing 

agents in swi ne. 

., 
6. 	 Dr. Charmi Mendis-Handagama: Regulation of 

mesenchymal cell differentiation into Leydig in the neo­
.. 
natal rat testis. .. 
7. 	 Dr. Joyce Merryman: The role of c:lun amino-terminal .. 
kinases 	in squamous carcinoma of the lung. 
.. 
8. 	 Dr. Linda Munson: Role of platelet-derived growth fac­
.. 
tor in endometriosis and endometrial carcinoma. 
.. 
9. 	 Dr. Jack Oliver: Vascular cell injury by toxicants of tall .. 
fescue grass. 
10. 	 Dr. Steve Oliver: Characterization of M proteins from 
environmental streptococci and evaluation of role in 
the pathogenesis of bovine mastil"is. ­.. 
1 1 . 	 Dr. Bart Rohrbach: InvestigO'l'ion of role of endo­
phyte-infected tall fescue as a risk factor for laminitis in the -.. 
horse. 	 .. 
12. 	 Dr. Barry Rouse: Evaluation of the kinetics and the .. 
mechanism by which mouse IL-l 0 induces suppres- .. 
sion. 	 .. 
1 3. 	 Dr. Hildegard Schuller: Molecular biology of neu­ .. 
rotransmitter receptors in lung cancer .. 
14. 	 Dr. Terry Schultz: Structure-activity relationships for skin .. 
sensi'l'izing chemicals: nitrogenous aromatic electrophiles. .. 
15. Dr. Erby Wilkinson: SCURFY; genetic identifica- .. 
tion of the and immunobiology. .. 
Equipment 	 .. 
Requests from 1 3 investigators for of equipment were .. 
funded by of over the past year. The investigators .. 
benefiting from these Center grants were Drs. David Bemis/Steve Kania, .. 
David Brian, Alan Mathew, C. Mendis-Handagama, Darryl Millis, Jack .. 
Oliver, Stephen Oliver, Barry Rouse, Terry Schultz, Hildegard Schuller, .. 
Hwa-Chain Wang and Dan Ward. Criteria taken into consideration for 
allocation of funds included justification of need, uipment avail­ .. 
ability in adjacent laboratories, and the number of investigators who .. 
benefit. •
..
..Student Awards 
..One mechanism by which the Center of Excellence promotes bio­
..
medical research is to provide summer opportunities for veterinary students 
.. to do investigational in research laboratories of the College of Veteri­
.. 
nary Medicine. This past year Center funded eight requests from first­
..
and second-yea students. At end of the summer, they provided a 
..
summary of their work to entered into a competition judged by Phi 
..
..6 	
..
.. 
., 
., 
Zeta, the veterinary honor society. The program appears to be 
., 
very successful; several students presented their findings at notional 
scientific meetings, and several manuscripts have been submitted 
for publication in peer-reviewed journals . 
., 
., 
., Personnel Changes 
.. 
., The Center is sure to benefit by the recent recruitment of two 
investigators Drs. Hwa-Chain Wong and Joseph Bartges, who 
., were provided with generous COE start-up funds this post year. Dr. 
., Wong's expertise is in molecular mechanisms involved in cancer 
., and Dr. Bartges interest is in animal models of nutritional diseases . 
., Dr. Edward Schroeder, Director of the Office of Laboratory 
Animal Core, retired during the year. We are pleased that this 
position was filled promptly by Dr. Dorcas Schaeffer following a 
., notional search. The College is currently conducting a search to fill 
., the remaining open laboratory animal veterinarian position . 
., The Deportment of Animal Science announced that Dr. 
Patricio Tithof joined the deportment to fill a position in physiology 
in July. Dr. Tithof's research interest is in line with the Center's focus 
and we look forward to her participation. 
., Dr. linda Munson, who hod been supported by the Center 
., for several years, resigned in August 1997. I hope that in the near 
future the College will receive approval to fill her position, in addi­
., tion to one in the Deportment of Animal Science. These positions 
have hod significant research assignments and could improve the 
., critical moss of the Center of Excellence . 
., 
., Funding Levels 
The toto I fu nd i ng for the Center of Excellence has not 
., changed significantly. Both extramural and state funds have re­
., mained steady. The state's investment in the Center of Excellence 
., in Livestock Diseases and Human Health remains a healthy one; 
., our extramural funding still is good, in spite of a difficult and very 
., competitive funding climate . 
I am very encouraged in that several faculty this post year 
., have secured new multi-year funding for COE-related research . 
.. They include: 
Dr. Jack Oliver: Reactivity of bovine vasculature to 
ergovaline and ergine of toxic toll fescue. From the No­
tional Research Initiative of the United States Deportment 
of Agriculture. Total award $188,000. 
-
., 
., 
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..Dr. Terry Schultz (co-investigator): role of bio 
a va i Ia b iii ty i n de t e r min i n g a c c e pta b Ieli mits for the 
.. 
bioremediation of polychlorinated biphenyls. From the rt­
ment Energy. Total award $44 1 

... 
... 
Dr. Hwa-Chain Wang: Pathway leads to apoptosis in SRC­

transformed From the National Cancer Institute (NIH). 

.. 
Total award $517,500. 
... 
.. 
Dr. Stephen Oliver: (a) Influence of prepartum intramam­

mary infusion Pirsue or Albacillin on mastitis and lactational 

... 
performance of heifers. From Pharmacia and Upjohn Company. 
... 
Total award $65,000; 
... 
(b) Lactation/Mastitis Research. From the I. Schattner Founda­
... 
tion, Inc. Total award $65,000; .. 
(c) Evaluation specific immune re sponses and protection 

during early lactation following immunization during the non-

lactating period with streptococcal antigens. From Pfizer, 

... 
Inc. Total award $ ,000. .. 
I look forward to another good year for the of Excel-

in livestock and Human Health. I am confident that the 
 ... 
support provided by the Center for some of our promising investigators ... 
will consitute the embryogenesis of established research programs. .. 
... 
,. 
.. 
...
.. 
.. 
... 
... 
.. 
.. 
.., 
..
.. 
... 
... 
.. 
.. 
... 
..
.. 
... 
..
.. 
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RESEARCH TRAINING 

Dr. David Slauson (center) 

with (from left to right) 

Dr. Sharon Witonsky, 

Dr. Barbara Sheppard, 

and Dr. Brian Julio 

Dr. David Slauson 
The College of Veterinary Medicine funds at least ten 
positions for Ph.D.-level training of students with a professional 
medical degree. Some of these students are based in the De­
partment of Pathology (as part of their residency/ Ph.D program), 
and some are awarded without restriction . Most of these stu­
dents become linked with investigators conducting Center of 
Excellence-related research. The presence of this dynamic group 
of young investigators significantly bolsters the achievements of 
the Center. Faculty benefiting from these graduate students in­
clude Drs . Rouse, Schuller, Wilkinson and Potgieter. 
In addition, the University of Tennessee College of Vet­
erinary Medicine is one of few veterinary colleges to be chosen 
as a site for a NIH Institutional Training Grant. 
This five-year training grant on the "Molecular 
and Cellular Pathobiology of Environmental Dis­
ease" is funded through the National Institutes of 
Environmental Health Sciences. The grant be­
gan in 1995 and is funded through the year 
2000; current annual funding is $122,968. This 
training grant, initiated by Dr. David Slauson, is 
centered in the Department of Pathology, but also 
involves scientists from other departments, as well 
as important collaborators in the life Sciences 
Division at the Oak Ridge National Laboratory. Dr. David O. 
Slauson, Program Director for the grant and Pathology Depart­
ment Head, said that the NIH funds provide stipend support for 
three years of advanced research training for DVM graduate 
students who already have at least two years of disease-ori­
ented residency training. "We are very honored to have been 
selected for this important award," Slauson said. "As far as I 
know, we are one of only two Colleges of Veterinary Medicine 
in the entire country to have such an environmental pathology 
training grant." Slauson indicated that the research training spon­
sored by this new NIH grant emphasizes basic molecular and 
cellular biology of disease, including environmental disease. 
"Our purpose here is to produce well-trained individuals who 
understand disease at the tissue and whole animal level, as 
well as at the most sophisticated edges of contemporary mo­
lecular and cellular pathogenesis," Slauson continued. There 
9 
are currently three DVM graduate students supported by these NIH 
funds and working in the laboratories of COE-associated scientists. 
The summaries below illustrate the sort of quality individuals 
that we have been able to attract to the University of Tennessee with 
this NIH Training Grant: 
Dr. Barbara Sheppard is working on the Ph.D. degree in 
Dr. Hildegard Schuller's Experimental Oncology Laboratory on 
a project involving growth regulation of the cells of origin of 
small cell lung cancer. Dr. Sheppard received her B.S. degree 
in biology from Virginia Polytechnic Institute in 1986 where she 
was on the Dean's list for her lost seven consecutive semesters. 
Dr. Sheppard then received a M.S. degree in physiology in 
1989, also from VPI, and was awarded her D.V.M. degree 
from North Carolina State University in 1993. Dr. Sheppard 
was in private practice in Delaware for a year before entering 
the Pathology Residency Program at the University of Florida in 
1994. Dr. Sheppard came to the University of Tennessee in 
1996 to begin her graduate program. 
Dr. Brian Jull is working on the Ph.D. degree in Dr. Schuller's 
laboratory, pursuing a difficult project that involves defining 
metabolic pathways involved in the regulation of growth of 
cells that become small cell lung cancer cells. Dr. Jull received 
his undergraduate degree in Animal Science cum laude from 
the University of Kentucky where he was a consistent member 
of the Dean's list. He received his D.V.M. degree summa cum 
laude, near the top in his class from the College of Veterinary 
Medicine at Auburn University in 1993. Dr. Jull was in private 
practice in Kentucky before joining the pathology residency 
training program at the University of Tennessee in 1995. Dr. 
Jull was appointed to the NIH training grant in 1997. 
Dr. Sharon Witonsky is working in Dr. Erby Wilkinson's 
Cellular Pathobiology Laboratory on projects involving mouse 
models of genetic diseases. Dr. Witonsky was a Phi Beta Kappa 
undergraduate in biology and chemistry at Earlham College, 
and received her D.V.M. degree from the University of Minne­
sota in 1993 where she was an outstanding student. She came 
to UTCVM in 1993 as a graduate student, and has been en­
gaged in research as well asclinical training in internal medi­
cine here, aiming at specialty board certification and a Ph.D. 
degree in Comparative and Experimental Medicine. Dr. 
Witonsky was appointed as an NIH Postdoctoral Fellow in 
1997. 
10 
"We believe that the graduates of this program will be able to 
contribute to an enhanced understanding of the environmentally-caused 
disorders of man and animals," said Dr. Slauson," both in terms of the 
morphologic expressions of disease and in terms of its molecular and 
cellular pathogenesis. "With trainees of this quality coming out of the 
University of Tennessee, College of Veterinary Medicine, we can all 
be rather proud," said Dr. Slauson. 
11 
INFLAMMATION 
LABORATORY 
Dr. Philip N. Bochsier 
Fellows and staff: Dr. Z. Yang, Dr. Gary L. Mason 
Pneumonia, mastitis, and enteritis/diarrhea of newborns 
are all diseases which result in significant economic loss 
for cattle and dairy operations in Tennessee. Leukocytes 
(white blood cells) are an important part of the immune 
system and contribute to defense against many of the in­
fectious agents which cause these diseases. Yet the rea­
sons for occasional breakdown in the defense systems 
often are unknown. The main focus of Dr. Bochsler's labo­
ratory is the basic mechanisms by which leukocytes can 
prOVide protection aga inst infectious agents that affect 
cattle. The research concentrates on the actions, interac­
tions, and synthesis of immunologically active products of 
white blood cells and cells lining blood vessels. Of par­
ticular interest is the responses of these cells to a compo­
nent (endotoxin) of certain bacteria (Gram negative), that 
commonly cause serious bovine diseases. Better under­
standing of bovine white blood cells and the immune system will 
help uncover the essential events in disease production by infec­
tious agents. This information should eventually frame the basis for 
improved strategies of prevention and therapy. 
When liberated from gram-negative bacteria in sufficient 
quantity, bacterial endotoxin elicits symptoms and adverse effects 
that may progress to multiple organ failure and death. Endotoxin 
binds to various substances in the blood, and on certain cells, is 
part of its action and metabolism. Dr. Bochsler determined that, 
unlike humans, the receptor to which endotoxin binds is present on 
the surface of bovine blood vessels. This suggests that these cells 
have a very high sensitivity and low activation threshold to this 
bacterial toxin. It explains also some aspects of important vascular 
and white blood cell responses to endotoxin in several diseases of 
cattle. He also was able to isolate and analyze the gene encod­
ing the surface structure (receptor) of the vascular lining cells to 
which endotoxin binds . 
Dr. Bochsler has investigated the factors affecting nitric ox­
ide production in lungs of cattle. Nitric oxide (NO) is a short-lived 
Dr. Philip N. Bochsler. 
12 
chemical reactant produced by many cells of the Bac:teria ­
body, and has an important role in host defense 
against certain microbes, such as bacteria. He '~' 
showed that nitric oxide is produced by lung scav­ @yLBP 
enger cells (alveolar macrophages) , but the ques­
<1'§)-LBP Immuno'log1ction of whether sufficient quantities of this substance 
Other andtis produced for bacterial killing remains unan­ r<J1icrobial ... L6P InOammatory 
swered. It was determined also that common res­ AflllgenS? ~'. '. , ~ ...·. esponses. R
piratory tract viruses of cattle (herpes and parain­ ~?~ . tJ'/, 
fluenza) impairs production of nitric oxide by al­ ~--,,~veolar macrophages. t Gef1~ Another approach taken by Dr. Bochsler and t Products 
his group was to determine the relationship be­ t " 
tween bovine respiratory virus infection and fibrin 
formation in the lung . Fibrin formation in the lung 
is important because it is a common complicating Mechanism by which bac­
factor in bovine pneumonia and may interfere with successful 	 terial products (LPS) at­
tach to scavenger cells
resolution of the disease. (macrophage) causing the 
They found that inoculation of lung scavenger cells with 	 release of biologically-ac­
tive products. 
a variety of bovine respiratory viruses increased production of 
a substance (tissue factor) that is an initiator of fibrin formation. 
A bacterial component (endotoxin) often enhanced production 
of this substance by virus-treated scavenger cells . This work 
has advanced our knowledge of the mechanisms involved in 
the development of bovine respiratory tract disease. 
Dr. Bochsler's research has been supported by the Cen­
ter of Excellence and USDA. 
13 
Dr. Brian's interest in basic molecu­
lar biology has resulted in discoveries of 
fundamental biological mechanisms of vi­
rus and cell replication for which he has 
received national and international recog­
nition. His research exploits basic viral and 
cell biology discoveries for the control and 
therapy of important viral diseases of ani­
mals and people. 
Coronaviruses cause some of the 
most costly respiratory and gastro-enteric 
diseases among livestock and fowl and dis­

abling diseases of people. Efforts to control coronavirus infections 

have been frustrated by three major obstacles: 

1 . 	 A weak immune responses in animals to coronavirus 
vacci nation. 
2. 	 A logistical problem of inducing protective mucosal 
immunity in the newborn (often the most vulnerable 
victim of coronavirus infection). 
3. 	 An ability of coronaviruses to rapidly mutate into 
new pathogenic variants . 
The pri ma ry resea rch focus in Dr. 
Brian's laboratory is the molecular biology of 
coronavirus replication with the goal of de­
termining how this virus induces disease. They 
have discovered a fragment of the virus gene 
(subviral replicon) of the bovine coronavirus 
that replicates in the presence of Wild-type 
virus. This minigenome is being engineered 
experimentally to carry many kinds of poten­
tial antiviral molecules into cells . One mol­
ecule is an enzyme (ribozyme) designed to 
VIRUS MOLECULAR 
BIOLOGY LABORATORY 
Dr. David A. Brian 
Fellows and Graduate Students : Dr. Savithra Senanayake, 

Dr. Jennifer Black, Gwyn David Williams, Catherine Cardullo 

Dr. David A. Brian. 
Dr. Brian and staff. 
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.. 	
destroy the on which the virus depends for repli­
cation (polymerase gene). novel therapeutic ap­
.. proach could cure a virus-infected . Another mol­
.. 
.. 	
ecule is a gene for protein (antigen) that might 
.. 	
stimulate superior immunity against the coronavirus 
.. 	
when inoculated into animals . 
With funding from the USDA and the and 
modest support from the Center of Excellence, they 
., 
are making an intense systematic effort to under­
., 
.. 	
stand how five separate genetic structural elements in 
the coronavirus gene (genome) fundion to regulate 
production of viral proteins. This information will have 
.. 
 Figure 1: Electron micro­

scope of bovine coronavirus 
replicating in human prostate 
., 	 cells. This is the first evidence 
of susceptibility of human 
prostate cells to coronavirus 
infection. Corona-viruses are 
identified by arrowheads. 
.. 
.. 
., 
., 
Figure 2: Replication scheme 
for coronaviruses. Adapted 
from K. Holmes and M. Lai, 
Virology, 1996. 
., 
.. 
.. 
.. 

.. 

.. 
.. 
., 
a significant impact in designing additional control 
therapeulic strategies for coronaviruses. 
Through the study of the nigenome, Dr. Brian recently 
discovered regions at ,the ends of the virus genetic material that 
are potential sites for targeted antiviral (promoter regions 
for the virus' replicating enzymes). 
Of great interest is how a newly discovered segment in 
virus gene regulates replication the genome. structure 
is absolutely required in its entirety for genome replicaj'ion (RNA 
pseudoknot a tRNA-like structure - in the 3' end of bovine 
coronavirus genome). The hypothesis is that the RNA pseudoknot 
regulates produdion of viral which first must be accom­
plished before viral genetic material can be . By un­
derstanding how this structure regulates this function, it may be 
possible to develop a therapeutic antiviral molecule. struc­
ture-function relationship described for pseudoknot is novel; 
its function in this role (as 
mRNAs (+) 
a transfer RNA-like 
ment) apparently has not 
described any 
animal virus. An 
additional hypothesis is 
that the tRNA-li 
pseudoknot bi nds to a 
common cellular protein 
component of protein 
produdion machinery 
(his'l'idyl tRNA syn 
thetase). use the 
latter is involved in poly­
(as an antigen), 
an autoimmune 
in humans, a connection 
15 
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.. 
..between coronavirus infection and autoimmune disease may exist. If so, 
.. 
this would also a novel fi ng and may uncover a means by which 
.. 
particular disease could controlled. 
..
.. 
..
..
..
.. 
..
.. 
..
.. 

.. 
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.. 
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TUMOR BIOLOGY 
LABORATORY 
Dr. Kevin A. Hahn 
Staffand Graduate Students: Dr. Ahmed Shoieb, MaryAnne Barnhill, 
Tracy Diehl, Marie Nolan and Jason Yarbrough 
Dr. Kevin Hahn. 
Many tumors and cancers can be treated effectively w ith 
certain drugs. Unfortunately, resistance to several drugs is becom­
ing a serious problem in cancer therapy. Dr. Hahn 's working hy­
pothesis is that modification of the activity or function of a certain 
enzyme (glutathione-S-transferases) will result in the reversal of anti­
cancer drug resistance and improve patients ' response to therapy. 
Dr. Hahn 's approach to confirming this hypothesis is to exploit a 
specific inhibitor of this enzyme and to determine whether it can 
reverse drug resistance in different systems. 
Earlier work by Dr. Hahn established 
that the enzyme (glutathione-S-transferases) 
is responsible for resistance to the d rug 
cisplatin and that the inhibitor (ethacrynic 
acid) reversed this resistance in cancer cells 
grown in the laboratory. Dr. Hah n cu rrently 
is evaluating whether the inhibitor can re­
verse the drug resistance in an animal. He 
is using an animal model consisting of the 
nude mouse, implanted with drug resistant 
tumor cells or with drug sensitive tumor cells 
for comparison purposes. Dr. Hahn has 
shown also that the blood concentration of the enzyme (glutathione­
S-transferases) is correlated with the successful treatment with an­
other drug (doxorubicin) of dogs with lymphoma. Therefore, moni­
toring blood concentrations of this enzyme regularly during treat­
ment may allow clinicians to identify drug-resistant patients early 
and initiate alternative treatments. This would decrease the likeli­
hood of subsequent remissions and extend patients ' life span . 
In another approach to improve cancer therapy, Dr. Hahn 
is using a dog model in an detect the recurrence of lymphoma 
before it is clinically apparent. In this study they measured the 
concentration of a substance (ACid Glycoprotein) in blood in sev­
eral dogs during clinical remission after haVing had lymphoma and 
treatment with doxorubicin . They found that blood concentration of 
17 
Acid Glycoprotein increased significantly just prior to the onset of a re­
lapse. Therefore, an elevated level of this substance is useful in predicting 
lymphoma progression in patients after treatment. This also should be very 
useful in the management of drug-resistant tumors . 
This research is funded by the Center of Excellence, Morris Animal 
Foundation a nd the Bayer Corporation. 
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TALL FESCUE 
TOXICITY LABORATORY 
Dr. Jack W. Oliver 
Staff: Dr. Eric Schultze, Dr. Robert Linnabarry, Kim Abney, 
Elizabeth M. Bailey and Jane Czarra 
Dr. Jack W. Oliver. 
Tall fescue is the predominant cool-season grass grown in 
Tennessee and much of the Southeastern United States, and is 
common forage for cattle and other grass-eating species (herbi­
vores). Most of the tall fescue grown in the U.S. is infected with a 
fungus (Neotyphodium coenophialum) that produces po­
tent chemical agents known as ergot alkaloids. These 
alkaloids are harmful to livestock and result in serious eco­
nomic losses to producers. The tall fescue toxicosis syn­
drome in herbivores is widely recognized as the primary 
grass-induced toxicity for animals in the U.S. There are 
more than 3.5 million acres of tall fescue in Tennessee, 
approximately 10% of the total U.S. acreage. Annual 
animal production losses to the state due to livestock con­
suming the infected forage are estimated at 100 million 
dollars . Production losses occur because of severely im­
paired weight gain, milk production and reproduction in 
animals that consume contaminated grass. 
The ill effects caused by ergot alkaloids ("ergotism") 
is certainly not a new disease entity, having been recog­
nized in people for hundreds of years. The disease in 
humans is associated with the eating of grains contami­
nated with a fungus (Claviceps spp.-"ergotized") that produces 
alkaloids similar to those present in infected fescue grass . Tissue 
lesions in people caused by ergotized grains were described in 
the 1930s, and outbreaks of a similar disease in cattle identified 
in the 1950s was associated with grazing on Kentucky 31 tall 
fescue grass . The incrimination of fungus contamination of tall 
fescue grass as the cause of toxicity in cattle was made by a 
group of researchers at the University of Georgia in 1977. How­
ever, despite numerous studies at Southeastern Land Grant Col­
leges designed to understand and alleviate the disease problem 
and intensive discourse among researchers worldWide, produc­
tion losses continue in animals that graze contaminated tall fescue 
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grass. 
The long-term goal of tall 
fescue research is to prevent the 
health problems in herbivores that 
consume the grass, while main­
taining the drought and insect re­
sistance imparted to the plant by 
the presence of the fungus and 
the ergot alkaloids. Development 
of an effective vaccine or chemi­
cal treatment is needed to counter 
the toxic effects in animals, that 
would allowing full usage of this 
valuable forage . Alternatively, 
identifying the specific toxic alkaloids in tall fescue grass will allow 
plant scientists to genetically manipulate fescue grass to eliminate 
toxic alkaloid production. 
Research by Dr. Oliver and his co-workers on reducing the 
severity of the disease has, among other advances, resulted in de­
velopment of an effective anti-fescue toxicosis vaccine (U .S. patent 
awarded). The nutrient content of tall fescue is excellent and this 
forage could be exploited even more widely if the associated health 
problems in herbivores could be prevented . The grass is well es­
tablished, and valued for its vigor and root establishment making it 
an important factor in control of soil erosion, and an extremely 
popular turfgrass. 
The short-term goals of fescue toxicosis projects have fo­
cused on injury to cardiovascular tissues of animals consuming fun­
gal-infected tall fescue grass. Although much remains to be learned, 
excellent progress has been made. Dr. Oliver's work has estab­
lished that vascular damage may be the central event induced by 
ergot alkaloids in animals: 
1 . 	 The ability of blood vessels to contract is increased 
by changes in blood vessel structure (alpha-adren­
ergic-2 receptors) that trigger vessel narrowing. 
2. 	 Soluble chemical factors released by the cells that 
line blood vessels further produce vessel contraction 
and narrowing (thromboxane A2, angiotensin II). 
3. 	 Circulating ergot alkaloids from fungal-infected fes­
cue result in the release of factors that promote blood 
clotting (Von Willibrand factor) and damages lining 
cells of blood vessels. 
4. 	 Damage to the lining cells of blood vessels and the 
Figure showing tall fes­
cue use/adaptation . 
From R. Buckner & L. 
Bush (Eds.), Tall Fescue 
(1979), p.15. 
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associated attempt at repair (platelet aggregation and blood 
clotting), result in release of factors that cause vessel wall 
thickening (serotonin, thromboxane A2, angiotensin II). 
As a consequence of injury to blood vessels, blood 
flow to tissues is impaired thereby affecting the function of 
body systems . Examples include: 
1. 	 Decreased blood flow to the skin affects haircoat 
quality (unthrifty appearance) and contributes to 
heat stress in animals by interfering with heat loss 
from body surface. 
2. 	 Altered blood flow and blood clotting in the small 
vessels of lung tissues impairs oxygen distribution to 
tissues, and decreases heat loss via the lungs. 
3. 	 Altered blood flow to mammary tissues contributes 
to decreased milk production. 
4. 	 Altered blood flow to reproductive structures affects 
reproductive capacity. 
5. 	 Decreased blood flow to the intestines and the 
liver affect body metabolism and suppresses 
growth (decreased weight gains). 
The achievements of the researchers in the College 
was recognized in 1997 by an invitation to Dr. Oliver to 
deliver a plenary paper on the physiological manifesta­
tions of fescue toxicosis in ruminants at the Third Interna­
tional Symposium on Fescue Toxicity that was held in Ath­
ens, Georgia, May 28-31, 1997. Over 100 research­
ers from 14 countries attended this major, worldwide event. 
In October of 1997, USDA awarded a substantial com­
petitive research grant to Dr. Oliver and co-workers for 
three years to continue study of mechanisms of toxicity 
caused by the fescue alkaloids. The study will allow con­
tinued in-depth examination of toxic mechanisms of alka­
loids, and will establish relative toxic effects of the major 
alkaloids found in fungus-infected tall fescue. 
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MASTITIS RESEARCH 
LABORATORY 
Dr. Stephen P. Oliver 
Post-doctoral Research Associates and Staff: Dr. Raul Almeida, Dr. 
Weihuan Fang, Barbara Gillespie, Mark Lewis, Doug Luther, Susan 
Ivey, Lori Coleman 
Research conducted by Dr. Oliver focuses on mastitis in 
dairy cows caused by environmental organisms . Obiectives are 
to : 
1 . 	 Characterize factors that affect resistance of the 
udder to mastitis. 
2. 	 Characterize factors and mechan isms, that per­
mit mastitis pathogens to invade the udder and pro­
duce mastitis . 
3. 	 Develop and evaluate techniques for the preven­
tion and control of mastitis in dairy cows. 
Dr. Oliver's resea rch program incor­
porates both applied and basic research. 
Applied studies concentrate on issues of con­
cern to the dairy industry that can have an 
immediate beneficial impact. This research 
includes strategies for controlling mastitis in 
heifers and the influence of mastitis on re­
production of high-producing dairy cows. 
Basic research is aimed at discov­
ering innovative methods of mastitis control 
by exploiting biotechnological advances . 
This research includes development of 
nucleic acid probes for rapid and accurate detection of mastitis 
organisms and organisms responsible for food poisoning. Other 
studies being done concern virulence (severity) factors produced 
by and immunity to certain mastitis-producing organisms (strepto­
coccus species) in cows . They also are attempting to identify dis­
ease-resistant genes of dairy cattle. 
Mastitis is caused by several kinds of bacteria that are ca­
pable of infecting the udder. Mastitis pathogens invade the udder, 
Dr. Stephen P. 
Oliver (center) 
and staff. 
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Figure 1: Electron micro­
scope view of bacteria at­
tached to a milk-secreting 
cell. 
., 
., 
., 
mulliply there and produce harmful substances 
that result in inflamma"l"ion, reduced milk produc­
lion and altered milk quality. Control of mastitis 
is extremely difficult because of the many types 
and sources of mastitis pathogens that can cause 
the disease. The National Mastitis Council esti­
mates that mastitis costs U.S. dairy producers 
over two billion dollars annually. In Tennessee, 
losses due to mastitis may exceed $25 million 
annually. Thus, mastitis in dairy cows is likely 
the most costly disease affecting dairy produc­
ers in Tennessee, the U.S., and throughout the 
world. 
Dr. Oliver has increased the awareness of scientists, 
extension specialists, dairy producers, pharmaceutical companies 
and other members of the dairy community of the importance of 
environmental pathogens in bovine mastitis. Furthermore, he has 
discovered fundamentally-important information that is critical for 
controlling the heterogeneous organisms that cause mastitis. The 
ultimate goal of Dr. Oliver's research is to enhance the quantity 
and quality of milk produced by and to reduce the economic 
impact of mastitis for dairy producers in Tennessee, the U.S., and 
throughout the world. One aspect of this work is to develop a 
vaccine to prevent mastitis and thereby eliminate the need for 
treatment with antibiotics. 
Dr. Oliver was the first to show that mastitis in pregnant 
dairy heifers occurred frequently near calving and that many of 
these infections persisted into early lactation. His research has 
resulted in a simple, effective and inexpensive method for control­
ling mastitis in heifers. Intra-mammary antibiotic infusion before 
calving, was shown to be an effective procedure for: 
1. 	 Eliminating many infections in heifers during late 
gestation. 
2. 	 Reducing the prevalence of mastitis in heifers dur­
ing early lactation . 
3. 	 Reducing the prevalence of mastitis in heifers 
th roug hout lactation. 
Several studies over the past 1 3 years at the UT Dairy 
Experiment Station involved collection of milk samples for micro­
biological evaluation at intervals before calving, during lactation 
and during the dry period. About 15,000 samples are collected 
and processed each year from cows in this herd. Data hom those 
studies have been computerized, producing perhaps the largest 
-
23 
... 

mastitis database in the world. It now is being 
exploited for retrospective studies and will pro­
vide valuable informaj'ion on the spread mas­
titis pathogens l as Streptococcus uberis 
and Streptococcus dysgalactiae, in h-pro­
ducing dairy herds. 
Recently they evaluated the influence of 
mastitis on reproduction in Jersey cows and 
found it profoundly impairs reproduction dur­
ing early lactation. Consequently, two propos­
als were funded by the American Jersey Cattle Associal"ion 
delineate mechan by which mastitis can influence reproduc­
performance. 
Dr. Oliver has been aCl"ively the identification of 
virulence (severity) factors produced by certain mastitis organisms 
(streptococcus and implical"ions of immunity to them. In 
ma ny do i ry Streptococcus a nd Streptococcus 
dysgalactiae are responsible for a h proportion of mastitis with 
varying degrees severity in lactating and non-lactating dairy 
cows. Strateg for controlling these masl'itis pathogens are poorly 
defined and inadequate. This research focuses on: 
1 . characterization of uberis and 
2. 	 Characterization of S. and S. dysgalactiae 
with particular emphasis on factors involved in ad­
Y"lCJr,CJn,'r. and invasion into mammary epithelial Is. 
3. Evalual"ion of immunity immunization of dairy 
cows with components uberis and S. 
alactiae. 
4. 	 rTlL~r·I".J=rl'=CC of experimental vaccines to S. 
dysgalactiae mastitis during the nonlactating 
Dr. Oliver's research group determined that S. uberis and 
dysgalactiae readily adhered to and invaded cells lining bo­
vine udder res 1 and 2). Chronic infections then may 
develoPI and intracellular protect these r'\/"'iI"TCJril/"'i 
from anti-microbial drugs and host mechanisms. Mastitis 
pathogens in the presence of mammary epithelial (lining) 
cells in the laboratory synthesize proteins not detected when 
ria are cultured alone. These unique proteins likely are involved in 
virulence of bacteria including their capacity to adhere and invade 
mammary epithelial Thus, of pathogens in 
laboratory in the of mammary epithelial cells may 
Figure 2: 	 Electron micro­
...
scope view of a section 
through 	a milk-secreting ... 
cell containing several bac­
...teria. 
.. 
... 
... 
... 
.. 
... 
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in expression of bacterial virulence factors similar to that which 
occurs in the animal . This important discovery will be exploited for 
the development of vaccines and management of mastitis. 
Dr. Oliver has communicated results of his research via 
scientific and popular press publications, and via presentations to 
several different target groups at state, regional, national and in­
ternational meetings and conferences. There is considerable inter­
est in this work throughout the dairy community, and Dr. Oliver has 
been a popular speaker and author on heifer mastitis and its con­
trol. In addition, Dr. Oliver has made several 
presentations to groups such as The Univer­
sity of Tennessee Agricultural Committee 
Board of Trustees, the Institute of Agriculture 
Development Board and the 21 st Century 
Campaign Steering Committee, Tennessee 
Agricultural Experiment Station Department 
Heads' Conference, and the Tennessee 
Higher Education Commission Center of Ex­
cellence Review team. This spring, Dr. Oliver 
has given presentations entitled "The Univer­
sity of Tennessee Mastitis Research Program : Making a Difference 
Through Research" to the Tennessee House of Representatives Ag­
riculture Committee, to The University of Tennessee Institute of Ag­
riculture Alumni Council, and to The University of Tennessee Insti­
tute of Agriculture Development Board and Agriculture Steering 
Committee for the 21 st Century Campaign. 
Dr. Oliver's research in mastitis was recognized by the 
UT Institute of Agriculture in 1998 with the Pendergrass Award. 
The award, named for former vice president for agriculture 
Webster Pendergrass, is presented in tribute to a faculty member 
who has contributed most to the fulfillment of the Institute's goals . 
Dr. Oliver's research has been supported for several years 
by the Center of Excellence, but his primary funding has been 
derived from substantial grants from foundations and the pharma­
ceutical industry. 
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VIRAL IMMUNOLOGY 
LABORATORY 
Dr. Barry T. Rouse 
Fellows, Staff and Graduate Students: Uday Kumaraguru, Teresa 
Sobhani, Dr. Johnson Thomas, Dr. I/a Davis, Massoud Daheshia, 
Dr. Shivaprakash Gangappa, Sirdhar Govindaswamy Dr. Nelly Kuklin, 
Shilpa Deshpande, Dr. Stewart Novinger, Dr. Zhiya Yu, and Sangjun 
Chun 
Dr. Rouse's research deals with the issue of how the body 
recognizes and interacts with viral infections. The virus they study is 
herpes simplex virus, an agent that affects up to 80% of mankind. 
This virus causes a variety of diseases, but is rarely lethal. Follow­
ing initial infection, the body usually fails to cast out the virus, and 
it persists in association with cells of the nervous system in a condi­
tion called latency. Unfortunately this state of affairs is not perma­
nent, since periodically some latently-infected 
nerve cells reverse their interaction, and new 
virus is produced which may cause a second­
ary expression of lesions. Such recrudescent 
lesions occur frequently in some individuals and 
are the cause of considerable pain and dis­
tress. Much remains unresolved regarding the 
nature of the interaction of the herpes simplex 
virus with its host. One such unresolved issue 
is why the reactivation episodes are clinically 
significant in some individuals, but unnoticed 
in others. A likely answer to this question lies in the effectiveness of 
one or more components of the immune defense system. However, 
this is a difficult issue to study in the human host. 
The Center of Excellence supports some aspects of this re­
search, but it is funded primarily by very substantial grants from the 
National Institutes of Health. Their research has generated na­
tional and international interest, and the laboratory is recognized 
as one of the premier viral immunology programs in the country. 
Value of Animal Models 
Dr. Rouse's approach to understanding the interaction be­
tween HSV and the immune system has been to use model infec­
tions in experimental animals, using the mouse and a variety of 
Dr. Barry T. Rouse. 
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1) Normal cornea (top photo) 
2) Diseased cornea (bottom 
photo). 
routes of infection. Thei r aim is to identify 
immune defenses that best correlate with pro­
tection, seeking a means of vaccination and 
immune manipulation to enhance the effi­
ciency of appropriate immune defenses. 
Immunity to Herpesvirus Infections 
Currently, Dr. Rouse's major approach is 
to use novel vaccines composed of nucleic 
acids, which encode selected proteins of HSV 
as a way of inducing protection. They com­
bine this approach with the co-administration 
of molecules that can manipulate the quality 
of immune responses induced. Thus, it is 
known that molecules (so-called cytokines) re­
leased by the body's own T lymphocytes and 
other white blood cells may profoundly influ­
ence crucial events of the immune response. 
Accordingly they have found that the pres­
ence of some of these cytokines results in 
prompt and effective immune induction 
whereas the presence of others may lead to 
a type of immunity that is less effective. They 
are exploring the use of DNA, encoding various cytokines, 
given at different intervals in relation to either infection or immu­
nization for their effect on the level of immune protection. Their 
results may provide clues useful for the design of future herpes­
virus vaccines. 
Disease Caused by Immune Responses to 
Herpesviruses 
The immune response to a virus is not always a benefi­
cial protective event. In some situations aspects of immunity 
seem to account for development of lesions. Such situations are 
usually referred to as immune pathologies. At least one dis­
ease process caused by herpes simplex virus infection may 
represent an immunopathological event, the Herpetic Stromal 
Keratitis (HSK) syndrome. HSK involves the cornea of the eye 
and is the most common infectious cause of vision impairment 
in the USA. Many thousands of persons are affected, and a 
significant number require corneal transplants. Dr. Rouse is 
attempting to understand the various events that result in kerati­
tis with the ultimate objective of finding steps amenable to ma­
nipulation for minimizing lesions. They have identified many of 
the host cells and their products involved in lesion development 
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in mice . They showed also that, if the ani­
mals are genetically unable to generate im­
mune responses or if certain aspects of im­
munity are suppressed, keratitis does not de­
velop. This is the primary evidence sup­
porting the notion that herpes keratitis is, in 
fact, an immunopathological lesion, i.e. 
without a response by the immune system, 
damage to the eye would not result. 
It would not be wise to totally sup­
press immunity in an attempt to control HSV 
because, without some immune protection, the virus may spread 
beyond local sites (such as the eye) and cause damage to the 
nervous system. This may have lethal consequences. There may 
be more subtle ways of adjusting the immune response such that 
protection will be preserved and pathology diminished. One way, 
discovered in Dr. Rouse's laboratory, that seems to accomplish this 
objective is to adjust the cytokine environment of the cornea using 
DNA vaccines encoding cytokines. One cytokine, called IL-10, 
appears particularly useful for this purpose. 
Although replication by the virus in the eye appears as an 
essential event to set off keratitis, they found that the continued 
presence of the virus is not needed for persistence of the inflamma­
tory process. Indeed it could be that the virus somehow sets off an 
inflammatory event that, in its latter stages, becomes an autoim­
mune reaction. 
According to this idea, herpes simplex virus may damage 
the cornea, causing a slight change in tissue composition such that 
it then becomes the target of the immune response. Some research 
results even suggest that a component of the virus itself may act as 
a molecular mimic of the host protein that then drives autoimmunity. 
Dr. Rouse and his co-workers are striving to evaluate these ideas on 
the role of the immune response in herpes keratitis using a variety of 
genetically-defined animal model systems. They hope that their re­
search will culminate in an understanding of the molecular and cell­
specific steps that occur during keratitis, and that clues will emerge 
as to how best to manage this tragic disease in people. 
Dr. Rouse and staff. 
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EXPERIMENTAL ONCOLOGY 
LABORATORY 
Dr. Hildegard M. Schuller 
Fellows, Staff and Graduate Students: Dr. Howard K. Plummer 
III, Dr. Diann L. Weddle, Dr. Barbara J. Sheppard, Dr. Brian A. 
Jull, Michelle R. Williams, and C. Brian Porter 
Dr. Hildegard M. 
Schuller. 
Lung cancer is the leading cause of cancer deaths in all 
industrialized countries . East Tennessee has one of the highest 
lung cancer rates in the nation. Although cancers at other or­
gan sites are more than twice as common , their cure rate is 
considerably higher. The most common cancer in men is pros­
tate cancer with a cure rate of 84%. Breast cancer is the lead­
ing type of cancer in women with a cure rate of 74%. By 
contrast, 158,700 (89 .3%) of the 177,700 patients diagnosed 
with lung cancer in the year 1997 died within 1 2 months of 
diagnosis . 
Smoking and exposure to second hand smoke are the 
most intensively studied and best-documented risk factors for 
the development of lung cancer. Contrary to cancers at other 
organ sites , the incidence of lung cancer continues to rise in all 
industrialized nations. Moreover, teen smoking in the U.S. has 
increased at an alarming rate, thus setting the stage for even 
higher numbers of lung cancer cases 30-40 years from now. 
Another important contributing factor to the rise in lung cancer 
cases is the growing number of lung cancers developing in 
individuals who have never been exposed to primary or sec­
ond hand smoke. This trend, which has been globally ob­
served during the last two decades in all industrialized coun­
tries, is particularly evident for pulmonary adenocarcinoma. Of 
the six types of lung cancer recognized by the World Health 
Organization (WHO) classification, two (small cell carcinoma 
and adenocarcinoma) account for 90% of all lung cancers, 
with 30% of these cases unrelated to a history of exposure to 
primary or second hand smoke. 
The lung cancer "epidem ic" is closely related to an in­
crease in chronic lung diseases such as bronchitis, bronchioli­
tis, asthma, emphysema , and chronic obstructive pulmonary 
disease. For all lung cancer types, chronic lung disease has 
29 
been identified as a risk factor even 
without a history of exposu re to 
smoke. This disease complex, 
which often is referred to as "aller­
gies," has the same geographic 
distribution as lung cancer with 
which it shares some risk factors 
such as smoking and air pollution . 
It has been stated that East Tennes­
see is "the land of allergies." 
Dr. Schuller's research has 
been dedicated to the study of lung 
cancer for over 20 years. It is her 
belief that effective strategies for the prevention and therapy of this 
disease complex can only be based on an in-depth understanding 
of the regulatory mechanisms which govern the growth of normal 
lung cells and the cancers arising from such cells. Contrary to 
other researchers who are searching for the "magic molecular event" 
responsible for the genesis of all lung cancers, she hypothesized 
that different lung cell types and different types of lung cancer may 
be governed by different regulatory mechanisms. These in turn 
may be differently affected by known risk factors for the disease. 
Dr. Schuller's achievements in lung cancer research have 
been recognized nationally and internationally. Her research has 
been supported by the Center of Excellence, but her primary sup­
port comes from substantial grants of the National Cancer Institute 
and the pharmaceutical industry. 
Recent Achievements 
Dr. Schuller's recent research has been prompted by the 
epidemiological evidence which links small cell lung carcinoma to 
both smoking and chronic lung disease. Her group is exploring 
whether factors exist unique to tobacco constituents and chronic 
lung disease that might interfere with growth regulation in these 
types of cancer cells and the normal cells from which they originate 
(pulmonary neuroendocrine cells). Using this approach, they found 
that the growth of these normal cells is regulated by an aspect of 
the nervous system (autonomic) via the release of a chemical mes­
senger from nerve endings (the neurotransmitter acetylcholine). They 
have identified the molecular mechanism that triggers specific growth 
of this cell type. The first discovery was that the chemical messen­
ger binds to a specific surface structure unique to these cells. 
They now have dissected the chemical events that are trig­
gered by the binding of the chemical messenger to the receptor. It 
Lung tumor induced in a 
hamster by a metabolic 
product of nicotine and 
increased intrapulmo­
nary carbon dioxide. 
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culminates in the release of a growth fac­
tor, serotonin, into the blood stream . The 
release of this growth factor selectively stimu­
lates the growth of the neurendocrine cells . 
Their studies showed that nicotine and its 
prod uct prod uced in the body sti m u late the 
production of high levels of this growth fac­
tor by binding to the receptor on these cells. 
Minute amounts of these tobacco-specific 
agents therefore act as powerful and selec­
tive growth stimulators for these cells in smok­
ers . Their experiments also showed that carbon dioxide selectively 
sensitizes the receptor to nicotine, thus dramatically promoting the 
release of the growth factor and growth stimulation in response to 
these tobacco-specific toxicants. 
Chronic lung diseases impair pulmonary ventilation, thus 
increasing the concentration of carbon dioxide in the lungs . The 
increased carbon dioxide therefore drastically increases the likeli­
hood for the development of small cell lung cancer in smokers . In a 
hamster model developed by Dr. Schuller, this hypothesis gains 
powerful support from their finding that nicotine and its metabolic 
product, which is non-carcinogenic in healthy animals, causes lung 
tumors in hamsters under conditions of increased intrapulmonary 
carbon dioxide. 
Their findings explain why small cell lung cancer is virtually 
never found in nonsmokers and why among those who smoke, this 
cancer type develops primarily in individuals with chronic lung 
disease. Moreover, these data prOVide a basis for the develop­
ment of novel drugs and treatments for this lung cancer type . 
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BIOLOGICAL ACTIVITY 
TESTING AND MODELING 
LABORATORY 
Dr. Terry W. Schultz 
Staff and Graduate Students: Glendon Sinks, Betsy Gregory and 
Anna Bearden 
Modern society uses and misuses hundreds of thousands 
of organic chemicals. While the need for information to aid indus­
try and government in hazard and risk assessment of chemicals 
has never been greater, only limited toxicological assess­
ment has been done on a small fraction of these chemi­
cals. At the same time the resources allocated to generate 
these data are being reduced. As a consequence, the 
field of structure-toxicity has been developed and is pro­
viding important answers in a timely and resource-efficient 
manner. Today, structure-toxicity models are considered re­
liable tools for use in hazard and risk assessment. Dr. 
Terry W. Schultz, at the University of Tennessee's College 
of Veterinary Medicine has been a leader in the develop­
ment of this science. 
Structure-toxicity relationships correlate toxic potency 
of chemicals to their chemical properties. Since proper­
ties of chemicals are related to their structure, structure­
.. 
toxicity studies investigate the sort of chemical structure that will Dr. Terry W. Schultz. 
produce a well-defined adverse or toxic response. Structure-toxic­
ity studies have been conducted for over a century. A. F. A. Cros 
defended his thesis entitled: "Action de I'alcool amylique sur 
I' 0 r g ani s me" before the Fa cui ty 0 f Med i ci n e , U n i ve r s i ty 0 f 
Strasbourg, Strasbourg, France on January 9, 1863. He noted 
the relationship between the toxicity of simple alcohols and their 
water solubility. This relationship demonstrated the central axiom 
of structure-toxicity modeling - the toxicity of molecules is reflected 
in their chemical structure. The science of structure-toxicity is truly 
an integrated one (see figure, opposite page). 
The objective of structure-toxicity analyses is to define, as 
accurately as possible, the limits of variation in the structure of a 
chemical that are consistent with the production of a specific toxic 
effect. Moreover, such analyses examine ways in which alter­
ations in structure and overall properties of the molecule influence 
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Quantifiable toxicology 
involves numerous dis­
ciplines. 
toxicity. If enough data related to toxicity become available, a 
hypothesis can be developed regarding the molecular basis of in­
teraction between the toxicant and the site of its toxic action in the 
body or cell . 
Dr. Schultz directs the Biological Activity Testing and Model­
ing Laboratory in the College of Veterinary Medicine at the Univer­
sity of Tennessee, which has had a long-standing interest in struc­
ture-toxicity modeling . The U.S. Department of En­
ergy and the U.S. Environmental Protection agency 
are the primary sources of funding for this research. 
The Center of Excellence also has invested in this 
research, which during the past 15 years it has pro­
vided expertise to industry and agencies not only in 
Tennessee, but also to the entire nation . Moreover, 
Dr. Schultz has built a solid international reputation 
in the field through collaborative efforts throughout 
the world. 
Since the establishment of the Center of Excellence in live­
stock Disease and Human Health in 1985, the Biological Activity 
Testing, and Modeling Laboratory has tested an average of more 
than 100 chemicals per year. This work has developed the largest 
chemical toxicity database in the world . The long-term goal of this 
program is to develop a computer-aided , knowledge-based system 
that will predict acute toxic potency from molecular structure. The 
current version accurately models the toxicity to humans of about 
75% of the industrial organic chemicals . 
The short-term goal of this program is to develop a better 
understanding of man-made chemicals that cause disruption of en­
docrine (hormonal) systems. In particular, their current project fo­
cuses on identifying the molecular structural features associated with 
industrial organic chemicals that mimic estrogens . Recent achieve­
ments by this group include the prediction of the capacity for chemi­
cals to form highly toxic , free radicals (reactive products) by certain 
biochemical mechanisms (either by photo-induction or by mimick­
ing synthetic cytochromes). 
As we enter the 21 st century, the Biological Activity Testing 
and Modeling Laboratory stands ready to assist industry and gov­
ernment to address toxicological problems by acquiring specific 
data and to develop tools to be used in predicting toxicity from 
molecular structure. 
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ANTICANCER MOLECULAR 

ONCOLOGY LABORATORY 

Dr. Hwa-Chain R. Wang 
Dr. Wang's long-term research goals concern tumor-spe­
cific intracellular molecular signaling network and to uncover sig­
naling pathways that can be induced by anticancer agents, lead­
ing cancer cells to a programmed cell death (apoptosis) . 
Short-term goals are to identify intracellu­
lar signaling elements whose activation is in­
volved in induction of apoptosis of cancer cells. 
A corollary to this is to identify novel anticancer 
agents which may selectively induce apoptosis 
of cancer cells, while sparing normal cells. Ulti­
mately, he expects to apply the understanding 
of intracellular signaling control to anticancer 
therapeutics . 
Currently, Dr. Wang focuses on two ap­
proaches. The first is to understand the molecu­
lar and cellular function of a novel intracellular 
enzyme, which is activated in cells at the late stage of cellular 
malignancy and in cells undergoing programmed cell death in­
duced by forms of acute stress. The second is to study molecular 
and biological activities of a novel natural anticancer agent, which 
selectively induces programmed cell death of cancer cells . 
Dr. Wang has identified a novel enzyme (kinase SAMK/ 
Krs 1 ) that is activated in cells at the late stages of transformation 
into cancer cells . The same enzyme is also induced in cells under­
going programmed cell death as a result of a variety of physiologi­
Dr. Hwa-Chain R. Wang. 
Dr. Wang and staff. 
cal, chemical or physical stresses. Dr. Wang 
determined that the gene encoding this en­
zyme might represent a member of a new 
kinase enzyme family. He is investigating 
the molecular and biological roles of this 
enzyme gene in cancer development and 
programmed cell death. Uncovering the ap­
parent novel signaling pathway that cross­
links cancer development of cells to pro­
grammed cell death should be directly ex­
ploitable for development of anticancer 
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therapeutics . 
Investigation into the mo­
lecular mechanisms of potential 
anticancer therapeutic agents 
on a variety of cancer cell types, 
particularly human breast can­
cer cells , is ongoing . Cancer­
ous mouse embryo cells and 
various human tumor cells are 
used to screen anticancer 
Research goals. 
agents. A novel natural substance was isolated from bacterial 
cultures, and Dr. Wang discovered , it induces programmed 
cell death in these cells whereas it merely inhibits growth in 
normal cells . Studies on the molecular activities of this drug on 
different intracellular metabolic signaling pathways suggest it 
selectively induces programmed cell death in cancer cells only. 
At least three important intracellular metabolic signaling path­
ways are affected. Dr. Wang has made progress in testing this 
phenomenon in cell cultures and is developing a unique model 
for testing in an animal model (mice) . In the latter, he hopes to 
determine the efficacy of this anticancer agent at different stages 
of malignancy. His research therefore is unique in that it links 
the molecular, cellular and animal system approaches in the 
development of anticancer agents. 
Dr. Wang's research is supported by the Center of Ex­
cellence, but his primary funding source is the National Cancer 
Institute . 
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MOLECULAR GENETICS 
LABORATORY 
Dr. J. Erby Wilkinson 

Fellows, Graduate Students and Staff: Dr. Carla Sommardahl, 

Dr. Sharon Witonsky, Dr. Joanne Zahorsky, Nancy Nielson, 

Marilyn Cottrell 

Dr. Wilkinson's primary research focus is defining the role 
of certain genes and gene products in specific diseases. Many 
diseases of people and animals are the result of the cumu­
lative effects of altered gene activity. Any given disease 
may result from the increased or decreased activity of nor­
mal genes, the activity of normal genes at the inappropri­
ate time or place, or the activity of a mutant gene. Most 
diseases are the result of the cumulative effects of all these 
molecular events. 
The group uses the tools of molecular and cellular 
biology, informatics, the emerging technologies of genetic 
manipulation of the mouse, and information generated in 
the Human Genome Project to develop animal models of 
human and domestic animal diseases. Unlike many other 
groups, all their efforts start with the identification of a mu­
tant mouse with a particular disease. They then use the 
skills of clinicians, pathologists, and other researchers to 
define the disease and identify the nature and effect of the muta- Dr. J. Erby Wilkinson. 
tion. r 
They are actively involved in the development and identifi­
cation of mutant animals, and have genetic 'tricks' to limit the num­
ber of animals needed to produce mutations in every gene in a 
specific region of chromosomes. By using "super mutagens," chemi­
cals that produce many mutations in a cell, they are able to qUickly 
produce and identify several mutations within a single gene. These 
types of mutations are particularly important because they repre­
sent a range of gene malfunctions that result in varying degrees of 
disease severity. This information is especially useful to the pharma­
ceutical industry, since any drug that is developed may only par­
tially inhibit or enhance the function of a specific gene and its 
metabolic pathway. 
In addition to these newest mutations, known as saturation 
mutants, the laboratory is also involved in the identification and 
analysis of spontaneous mutants and various mutants produced by 
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(top) Normal mouse. 
(bottom) Mouse 
with scurfy. 
genetic manipulations. They use all the tools 
of modern molecular biology and the tradi­
tional tools of immunology, pathology, in 
addition to developmental biology, to com­
pletely evaluate the role of specific genes 
in specific diseases . These studies, which 
are part of the federal government-spon­
sored human and mouse genome initiatives, 
include collaborations with a number of in­
vestigators at the Oak Ridge National Labo­
ratory. Several projects have matured con­
siderably in the past year, and several new 
projects have been initiated. 
They have identified a gene that causes a fatal congenital 
kidney disease in humans (polycystic kidney disease). The various 
forms of this disease represent a spectrum of diseases that are a sig­
nificant health problem worldwide . One form is a significant cause of 
mortality in newborns. In addition to closely mimicking human poly­
cystic kidney disease, this mutant line of mice is unique in that the 
mutant gene now has been cloned and characterized by Dr. Wilkinson's 
group. Thus, for the first time, a gene directly associated with poly­
cystic kidney disease was identified. Studies are underway to further 
define normal structure and function of this gene to determine how 
mutations in the gene result in the pathologic changes seen in the 
disease, and to identify other genes affecting the severity of the dis­
ease. 
In addition, they have identified and characterized unusually 
primitive cells in the livers and pancreas of these mutant mice. The 
existence of such cells and the impact of their manipulation may be 
important in the treatment of liver and pancreatic diseases. The re­
searchers also demonstrated recently that the polycystic kidney dis­
ease gene is an important factor in cancer of the liver, kidney, and 
pancreas . From these studies, possible new avenues of therapy can 
be explored. 
Other projects include the analysis of a number of mutations 
that alter the immune system . In one recently completed project, they 
determined the cellular basis for a severe, rapidly fatal disease of the 
immune system in certain (scurfy) mice. They are currently working 
with collaborators to identify the mutant gene and determine how it 
causes the disease . Another line of mutant mice has been analyzed 
because of a high incidence of tumors. The tumors have been char­
acterized and they anticipate cloning the mutant gene over the next 
year. Their data indicates that a unique, uncharacterized gene re­
sponsible for suppressing these tumors contains a mutation. 
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INFORMATION DISSEMINATION 
OF RESEARCH TO THE 
GENERAL PUBLIC 
Dr. Nancy Howell 
Providing the public with information about Center of Ex­
cellence research is an important activity of the College of Veteri­
nary Medicine . To accomplish the goal of 
disseminating research information, the col­
lege utilizes many resources. 
The college produces a general news­
letter twice annually, distributed throughout Ten­
nessee and beyond, which highlights research 
activities. Features on on-going research, in 
addition to results from concluded research 
are included in the publication, Veterinary 
News, which is written for general audiences. 
Features appear in other University of Tennes­
see publications, including UT Agriculture , UT 
Alumnus and Tennessee AgriScience. 
News releases are routinely distributed to state media, in 
addition to certain regional and national media . Television and 
print publications produce numerous features about the college 
each year, many related directly to research conducted through 
the Center of Excellence. Public displays about the college also 
frequently include highlights of COE research . In addition, Center 
of Excellence researchers are invited to share their research not 
only professionally, but as speakers to commodity groups, civic 
groups and other interested ind ividuals . 
Another method of information dissemination is through the 
college's site on the world wide web. Research is a major compo­
nent of the site, with some COE projects , such as the tall fescue 
toxicity research , including detailed information concerning their 
progress . 
Providing this material in the general media not only in­
forms the public of important information, but helps the public bet­
ter understand science and the practical applications of science to 
their daily lives. 
Research information 
is distributed through 
a variety of UT publica­
tions, as well as local 
and national media. 
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TABLE 2 

CENTER OF EXCELLENCE IN LIVESTOCK DISEASES AND HUMAN HEALTH 

BENCHMARKS OF FACULTY ACCOMPLISHMENTS 

FACULTY MEMBERS ASSOCIATED WITH THE CENTER OF EXCELLENCE 
YearS 
(Final Year of Initial 
Commitment Center) 
1988..1989 
Year 6 
(Year 01 as 
Accomplished Center) 
1989-1990 
Year 7 
(Year 02 as 
Accomplished Center) 
1990-1991 
Year 8 
(Year 03 as 
Accomplished Center) 
1991-1992 
Year 9 
(Year 04 as 
Accomplished Center) 
1992-1993 
Tar~et Actual Avq Actual Avg Actual Avg Actual Avg Actual Avg 
Number of: 
Articles 74 3.22 68 (2.62) 97 (3.73) 83 4.37 78 (3.90) 
Books or Book Chapters 7 0.30 17 (0.65) 14 (0.54) 6 0.32 7 (0.35) 
Published Proceedings 21 0.91 37 (1.42) 42 (1.62) 24 1.26 17 (0.85) 
Total Publications 2.82 102 4.43 122 (4.69) 153 (5.89) 113 5.95 102 (5.10) 
Abstracts 0.30 33 1.43 66 (2.54) 48 (1.85) 47 2.47 53 (2.65) 
Invited Participation at: 
Regional Meetings 0.50 36 1.56 19 (0.73) 28 (1.08) 13 0.68 15 (0.75) 
National Meetings 1.25 55 2.39 28 (1.08) 44 (1.69) 36 1.89) 47 (2.35) 
Faculty in Center 23 26 26 19 20 
Number of Visitors 10 17 17 12 12 
Year 10 
(Year 05 as 
Accomplished Center) 
1993-1994 
Year 11 
(Year 06 as 
Accomplished Center) 
1994-1995 
Year 12 
(Year 07 as 
Accomplished Center) 
1995-1996 
Year 13 
(Year 07 as 
Accomplished Center) 
1996-1997 
Year 14 
(Year 08 as 
Accomplished Center) 
1997-1998 
Actual Avq Actual Av~ Actual Avg Actual Avg Actual Avg 
Number of: 
Articles 95 (5.00) 132 6.29 153 (7.29 176 (7.33) 179 11.2) 
Books or Book Chapters 9 (0.47) 5 0.24 5 (0.27 5 (0.21) 104 6.5) 
Published Proceedings 11 (0.58) 37 1.76 65 (2.95 71 (2.96) 72 4.5) 
Total Publications 104 (5.47) 174 8.29 223 (10.62) 249 (10.38) 355 22.2) 
Abstracts 55 (2.89) 42 2.00 64 (3.05) 71 (3.01) 56 3.5) 
Invited Participation at: 
Regional Meetings 18 (0.95) 41 1.95 55 (2.62) 68 (2.83) 76 4.8) 
National Meetings 47 (2.47) 65 3.10 70 (3.18) 76 (2.92) 74 4.6) 
Faculty in Center 19 21 22 24 16 I 
Number of Visitors 13 15 18 18 19 I 
.lit
... 

Table 3 
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RESEARCH PROJECTS FUNDED EXTERNALLY 
REPORT PERIOD 1996-97 
PROJECT DIRECTOR TITLE OF GRANT FUNDING AGENCY TOTAL AWARDED ESTIMATED EXPENDITURES 
David Bemis Bordetella bronchiseptica adhesion molecules as 
protective immogens and markers of host specificity 
USDA 1433 Funds $ 9,000.00 
1% 1/96-9/30/97 
$ 5,444.07 
Bachsler Purification and characterization of bovine 
lipopolysaccharide.binding protein 
USDA $184,000.00 
8/31/97 
$ 78,651.80 
The role of nitric oxide as a mediator of host defense 
cattle 
USDA 1433 Funds $ 6,852.00 
10/01/95-9/30/96 
$ 6,852.00 
Mechanisms of innate resistance to enteric pathogens of 
bovine calves 
USDA 1433 Funds $ 8,322.00 
10/01/96-930//97 
$ 3,548.50 
David Brian Bovine coronavirus vector for mucosal immunity to 
phaemolytica leukotoxin 
USDA $140,000.00 
9/15/95·9/30/98 
$ 10,854.64 
Mechanism(s) of coronavirus RNA replication and 
packaging 
National Institute of Allergies and Infectious 
Diseases 
$228,871.00 
7/01/96·6/30/01 
$ 99,994.65 
Thomas Doherty Evaluation of gastric emptying in an endotoxin-induced 
ileus model in the horse 
USDA 1433 Funds $ 5,000.00 
10/01/96-9/30/97 
$ 1,195.00 
Donita Frazier Comparative cytochrome P450 drug metabolism 
pathways of fish, poultry, and swine 
USDA 1433 Funds $ 4,000.00 
10/01/96-9/30/97 
$ 101.00 
James Godkin Retinoids in bovine follicular and oocyte development 
K9TlnOla·Olnama protein and receptors in bovine 
Maintenance of pregnancy in cattle and 
USDA Formula Funds 
USDA NRI 
AES Hatch 
$ 5,000.00 
0/01/95-9/30/96 
$212,000.00 
9/01/93-8/31/97 
$ 15,000.00 
7/01/96-6/30/97 
$ 5,000.00 
$ 34,913.34 
$ 3,748.37 
Kevin Hahn Serodiagnosis of Doxorubicin resistance in dogs Morris Animal Foundation $ 3,000.00 
9/01/96-11/30/97 
$ 2,003.77 
Melissa Kennedy Detection f feline infectious peritonitis virus and 
differentiation from feline enteric coronavirus 
Morris Animal Foundation $ 19,000.00 
9/01/94-8/31/96 
$ 12,623.03 
Characterization of 7 A and 7B open reading frames of 
feline coronaviruses 
Pfizer Company $ 8,750.00 
7/01/96-7/31/97 
$ 8,699.75 
Identification and expression of FIPV.specific peptides 
and their use in FIPV-specific ELISA 
Morris Animal Foundation $ 23,725.00 
1% 1/96-10/31/98 
$ 2,666.56 
f f • • • ( • f • • • • • • C f • f • • • • • f C f f f • • • • • • f f • • f f • f • • • f • f f • • • f • • 
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Alan Mathew Evaluation of fiber blends, enteric microflora, and diet 
digestibility in cats with ileal cannulas 
lams \...VlIliJUIlY $113,054.00 
2/01/96-12/31/97 
$ 50,298.01 
Effect of volatile fatty acids on postweaning colonization 
of Escherichia coli and Salmonella choleraesuis in pigs 
USDA 1433 Funds $ 4,000.00 
10/01/95-9/30/96 
$ 4,000.00 
Charmi Mendis-Handagama 
Darryl Millis 
Weaning and colonization of E. coli in the intestine of 
young pigs 
Characterization of mastitis causing agents in swine 
Effect of galactosyl lactose on calf starter diets 
Regulation of testosterone production in adult rat testis 
Increasing the sperm counts in testes of bulls using the 
transient hypothyroid treatment 
The use of canine recombinant somatotropin to 
enhance fracture healina in dogs 
AES HATCH 
AES HATCH 
Snow Brand Milk Products Co. 
National Science Foundation 
URCEO, France 
Monsanto Company 
$ 52,000.00 
10/01//93-9/30/97 
$ 11,666.00 
1% 1/96-9/30/97 
$ 30,000.00 
$ 18,000.00 
8/15/94-1/31/97 
$ 24,000.00 
1/97-1/99 
$ 47,320.00 
5/01/96-7/01/97 
$ 
$ 
$ 
$ 
10,931.43 
1,666.00 
12,911.72 
39,320.22 
Pilot of a new anti-inflammatory for synovitis 
Length of treatment time with canine recombinant 
somatotropin for ostectomy healing in an unstable gap 
fracture healing model 
G.D. Searle and 
Protiva Company 
$ 50,749.00 
9/19/96-6/30/97 
$ 65,342.00 
01/01/97-12/31/01 
$ 
$ 
39,652.84 
30,519.79 
Initial dose determination of a new cylcoaxygenase-2 
inhibitor for the prevention of lameness induced by 
chemical synovitis in dogs 
Protiva Company $ 83,215.00 
06/01/97-5/31/98 
$ 11,359.47 
Modulation of osteoarthritis with somatotropin and 
Protiva $ 77,413.00 
06/01/97-5/31/99 
$ 4,202.03 
Linda Munson Contraceptive health surveillance center for zoo and 
wildlife species. 
Geraldine R. Dodge Foundation $ 30,000.00 
10/01/95-1/31/97 
$ 17,713.89 
Continuing safety assessments of contraceptives for 
non-domestic felids 
American Association of Zoo Parks and 
Aquarium 
$128,414.00 
1% 1/93-8/31 /97 
$ 50,829.84 
Contraceptive health surveillance center for zoo, 
wildlife, and companion animals 
Geraldine R. Dodge Foundation $ 25.000.00 
01/01/97-12/31/97 
Jack Oliver Characterization of serum clinical chemistry analyte 
profiles of cattle grazing endophyte-free and endophyte­
infected tall fescue grass 
USDA 1433 Funds $ 10,000.00 
1% 1/95-9/30/96 
$ 10,000.00 
~ 
W 
Anti-fescue toxicosis vaccine development USDA 1433 Funds $ 11,000.00 
10/01/96-9/30/97 
$ 11,000.00 
Anti-fescue toxicosis vaccine Merck and Company $ 60,000.00 
1/01/95-12/31/96 
polysulfated glycosaminoglycans in dogs using the 
Jack Oliver (continued) 
~ 
~ 
Stephen Oliver 
Sharon Patton 
Patton - Continued 
Bart Rohrbach 
Barry Rouse 
Endothelin response to tall fescue stimulus of bovine 
endothelial cells (Co-PI) 
Comparison of plasma cortisol concentrations after 
stimulation with freshly reconstituted and previously 
frozen and stored cosyntropin clinically normal dogs 
(Co-PI) 
The effect of exogenous oral melatonin administration 
on sex hormone proladin and thyroid concentrations in 
healthy sexually intact adult dogs (Co-PI) 
Identification, characterization, and evaluation of 
Streptococcus uberis virulence factors 
Efficacy of two novel experimental postmilking teat 
disinfectants for the prevention of mastitis in dairy cows 
under natural exposure conditions 
Influence of clinical and subclinical mastitis during early 
Iodation on reproductive performance of Jersey cows 
Influence of intramammary antibiotic therapy at 
on mastitis and lactational performance of heifers 
during early lactation 
Evaluation of specific immune responses and protection 
by novel streptococcal antigens 
lactation/mastitis research 
Hormonal changes associated with clinical mastitis 
during early lactation in Jersey cows (Co-PI) 
Toxoplasma gondii in swine populations: A comparison 
of the percentage of sows and market-weight pigs 
infected from the NAHMS, farm management practice 
relationships, and economic costs 
Epidemiology of Toxoplasma gondii in swine 
populations: A comparison of the seroprevalence of 
Toxoplasma gondii in hogs and market weight pigs in 
the NAHMS, farm management pradice relationships, 
and economic costs 
Randomized clinical trial to evaluate the effed of 
vaccination against Leptospira spp to prevent ERU in 
horses. 
Herpes zosterfilization 
USDA 
American College of Veterinary Dermatology 
American College of Veterinary Dermatology 
USDA Formula Funds 
Famam Companies, Inc. 
American Jersey Cattle Association Research 
Foundation 
The Upjohn Company 
Pfizer Company 
Robert l. Schattner Foundation 
American Jersey Cattle Association Research 
Foundation 
National Pork Producers 
USDA 1433 Funds 
Fort Dodge 
Smith-Kline Biological 
$ 60,002.00 
3/01/95-8/31/96 
$ 2,250.00 
7/01/96-6/30/97 
$ 3,000.00 
4/01/97-3/31/98 
$ 7,000.00 
1% 1/95-9/30/96 
$ 69,600.00 
1995-96 
$ 6,000.00 
1996 
$ 38,250.00 
1995-97 
$108,848.00 
4/97-12/98 
$ 65,000.00 
6/97 
$ 6,000.00 
1996 
$ 24,500.00 
9/01/96-8/31/97 
$ 11,000.00 
10/1/95-9/30/96 
$ 27,845.00 
5/15/97-8/15/-98 
$124,746.00 
7/1/90-12/31/04 
$ 7,000.00 
$ 3,395.19 
$ 20,534.00 
$ 10,454.21 
$ 11,000.00 
--- .. ------ ... __ .............. 
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Barry Rouse (continued) 
Mucosal immunity in control of herpetic infection National Institute of Allergy and Infectious 
Diseases NIH 
$728,711.00 
1993-97 
$ 209,616.29 
Immunity mechanisms in herpesvirus infections National Institute 
Diseases - NIH 
and Infectious $783,510.00 
1995-00 
$ 254,241.53 
Mechanisms of herpetic stromal keratitis National Eye Institute - NIH $1,047,093.00 
992-97 
$ 221,919.82 
Hildegard Schuller Anticarcinogenic effects of Dexniguldipine-HcL in 
hamster 
BYK Gulden $379,283.00 
1993-97 
$ 20,442.60 
NNK effects on receptor pathways National Institute of Health $599,126.00 
994-97 
$ 134,065.81 
Regulation of the proliferative response of pulmonary 
neuroendocrine cells to nicotinic agonists 
Verum Foundation for Behavior and 
Environment 
$128,484.00 
1/96-12/97 
$ 42,533.82 
Transplacental pancreatic carcinogenesis by NNI 
National Institute of Health $506,499.00 
7/31/97 
$ 184,945.48 
Terry Schultz Development of a bioremediation risk assessment 
scheme 
US Environmental Protection Agency $ 54,749.00 
9/94-9/97 
$ 5,443.27 
Structure-biodegradability/toxicity relationships of 
substituted naphthalenes 
Dupont Corporation $ 40,000.00 
6/95-6/97 
$ 40,000.00 
The role of bioavailability in determining 
environmentally acceptable endpoints for 
bioremediation of polychlorinated biphenyls 
(Co-PI) 
US Department of Energy $441,037.00 
3/97-2/00 
Photo-induced toxicity in Tetrahymena University of Minnesota $ 19,063.00 
1/94-12/96 
$ 19,063.00 
A. Eric Schultze Vascular cell injury by toxicants of tall fescue grass 
PI) 
USDA Formula Funds $ 5,000.00 
J. Erby Wilkinson Role of agouti gene in tumorogenesis Lockheed Martin $ 76,710.00 
10/01/95-9/30/97 
$ 41,562.97 
Collaborative studies on the cellular and molecular 
basis of disease in the scurfy mouse 
lockheed Martin $ 24,000.00 
7/29/96-7/28/97 
$ 21,208.71 
Genome analysis program Lockheed Martin $ 75,195.00 
2/96-9/30/97 
$ 38,971.91 
Histopathologic and clinical pathology analyses of mice 
from a colonv containing chromosomal translocations 
Lockheed Martin $ 102,250.00 
7/1/95-3/21/98 $ 49,181.39 
.I:a 
U'I 
Role of the agouti gene product on tumorogenesis Lockheed Martin 
$ 67,000.00 
7/01/95-12/31/96 $ 25,720.20 
J. Erby Wilkinson (confined) Directed expression of the agouti gene product in 
transfenic mice: A potential model for obesity 
Glaxo $ 672,890.00 
10/93-9/96 
$ 77,389.90 
A 
0­
Mammalian genetics and development Lockheed Martin $ 70,850.00 
10/95-9/96 
$ 21,924.52 
Mouse Lockheed Martin $ 41,391.00 
10/95-9/96 
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